Clonal Evolution

Miething (2019) — Clonal Evolution in Multiple Myeloma

Properties1
tagsprimary-research, clinical, selection

6 min read

Bibliographic Reference

Miething, C. C. (2019). Clonal evolution in myeloma: A narrow road to remission. Haematologica, 104(7), 1292–1293. https://doi.org/10.3324/haematol.2019.220152

Core Argument

This editorial comments on Jones et al. (2019), a study from the Myeloma XI trial that used whole exome sequencing of diagnosis/relapse pairs to examine clonal evolution in multiple myeloma during therapy. Miething argues that the depth of response to initial therapy is the primary determinant of clonal architecture at relapse: patients who achieve a complete response (CR) or very good partial remission (vgPR) undergo a clonal bottleneck that gives rise to branching evolution upon relapse, whereas patients with incomplete responses show linear evolution or stable clonal patterns. The editorial highlights a striking dissociation between the clinical benefit of lenalidomide maintenance therapy (improved disease-free survival) and its lack of impact on clonal patterns, suggesting an immune-dependent, non-selective mode of action rather than a direct selective pressure on the clonal composition. Miething frames this as a “narrow road to remission” — deep responses paradoxically select for diverse clonal escape mechanisms, raising the question of how to refine therapy to prevent the outgrowth of dormant resistant subclones.

Methods

This is an editorial/commentary. It discusses Jones et al. (2019), who performed whole exome sequencing (WES) on diagnosis/relapse samples from a subset of 56 uniformly treated newly diagnosed multiple myeloma patients from the Myeloma XI trial — 30 receiving lenalidomide maintenance and 26 patients without maintenance — with a focus on patients with high-risk disease and early relapse.

Key Findings

  • “Patients achieving a good response to the initial therapy [either a very good partial remission (vgPR) or a complete response (CR)] seemed to go through a clonal bottleneck leading to a branched clonal evolution upon relapse, whereas most patients with incomplete responses showed a linear evolution or stable clonal patterns.”

  • “The authors observed a change in the mutational spectrum and an increase in the mutation load in the majority of relapse samples, whereas only a subset of patients showed a stable mutational landscape.”

  • “Maintenance therapy did not significantly impact the clonal composition predetermined by the response category.”

  • “The authors did not identify specific mutations associated with relapse; for this type of analysis, higher patient numbers will be required.”

  • “Structural aberrations involving a gain of chromosome 1q or translocations targeting the Myc oncogene on 8q were increased at relapse, with additional evidence of bi-allelic inactivation of common tumor suppressor genes like RB1, TRAF3, and TP53 in a subset of relapse patients.”

Concepts Introduced or Used

  • Clonal bottleneck — A dramatic reduction in subclonal diversity caused by effective therapy, from which only resistant or dormant clones survive to repopulate at relapse. Deep response (CR/vgPR) in myeloma creates a tight bottleneck that paradoxically leads to branching evolution.
  • Branching evolution — A pattern in which multiple new subclones with divergent and partially distinct mutational profiles emerge from a common ancestor, typically following a strong selective bottleneck (clonal-evolution).
  • Linear evolution — A pattern characterized by sequential acquisition of additional genetic aberrations on top of existing mutations, maintaining the ancestral clone (clonal-evolution).
  • Clonal stability — A pattern in which the mutational spectrum remains roughly the same over the course of disease, with no significant clonal selection.
  • Minimal residual disease (MRD) — Disease present below the threshold of conventional clinical detection, measurable only by high-sensitivity flow cytometry or next-generation sequencing. MRD negativity correlates with improved PFS and OS in myeloma.
  • Clonal escape — The emergence and outgrowth of resistant clones from the residual clonal substructure after intensive therapy, leading to relapse.

Entities Referenced

  • Lenalidomide — Immunomodulatory drug (IMiD) used as maintenance therapy in the Myeloma XI trial; its mechanism relative to clonal evolution is discussed as potentially immune-dependent rather than directly selective.
  • Cereblon/IRF4 pathway — The canonical target pathway of lenalidomide; notably, only a few mutations in this pathway were detected in relapsed patients, supporting a non-selective mechanism.
  • RB1, TRAF3, TP53 — Tumor suppressor genes found with bi-allelic inactivation in a subset of relapse patients.
  • MYC — Oncogene at 8q24; translocations targeting MYC were increased at relapse.
  • Chromosome 1q gain — Structural aberration increased at relapse.
  • Whole exome sequencing (WES) — The assay used by Jones et al. to compare mutational profiles between diagnosis and relapse.
  • Myeloma XI trial — Large multicenter, open-label, randomized phase 3 trial of lenalidomide maintenance versus observation in newly diagnosed multiple myeloma (Jackson et al., 2019).

Limitations (as stated by author)

  • “The authors did not identify specific mutations associated with relapse; for this type of analysis, higher patient numbers will be required.”
  • “The maintenance lenalidomide dose and the more aggressive biology of the myeloma may have contributed to a reduced clonal selection pressure.”
  • “Alternatively (or additionally), maintenance therapy may not have had a sufficient effect on the overall clonal population such as to create an evolutionary bottleneck.”
  • “Future studies will need to look further into the effects of maintenance lenalidomide on clonal evolution to confirm these findings, and to expand the analysis to patients with less aggressive disease.”
  • The editorial also notes the limited dose (10 mg lenalidomide) as a possible factor reducing selective pressure.

Relevance to Clonal Evolution

This editorial documents a clinically critical instance of the therapy-response bottleneck in cancer evolution. The key finding — that deep response (CR/vgPR) creates a tight clonal bottleneck leading to branching architecture at relapse — directly illustrates the compression-entrenchment dynamic described in compression-progress-evolution and dual-regime-evolution: the very success of therapy compresses the clonal population, which then rebounds with greater diversity. This is the bottleneck paradox: better immediate response predicts more complex clonal architecture at relapse.

The dissociation between maintenance therapy’s clinical benefit (improved disease-free survival) and its lack of effect on clonal patterns is equally significant. Miething’s proposed interpretation — an immune-dependent, non-selective mode of action — suggests that not all therapeutic effects operate through direct clonal selection, a nuance that enriches the wiki’s treatment of therapy-resistance and clonal-sweep.

The editorial also raises a broader evolutionary question: how to prevent “clonal escape” from the residual substructure after intensive therapy, which it frames as the central challenge for achieving a cure in myeloma.

Graph View

Backlinks